trial

tDCS, Stress and Risk for Schizophrenia

NCTId NCT03217357
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 31 (actual)
Sponsored by Hôpital le Vinatier
Primary completion 2023-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-05-02
Primary completion
2023-06-30
Eligibility
ALL · 18 Years · 30 Years

Interventions & indications

Drugs
Transcranial stimulation in direct current

Sponsors

Hôpital le VinatierLead Sponsor

Investigators

1
D AMATO THIERRY, MD - PhDPrincipal Investigator

Sites

1 total
Bron, France

Facts & assertions

4 sourced
Enrollment
31
Phase
NA
Primary Completion Date
2023-06-30
Status
COMPLETED
relationships
The graph out of here
drug
Transcranial stimulation in direct current
drug
lead_sponsor
Hôpital le Vinatier
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
D AMATO THIERRY, MD - PhD
person